📋 Key Information Summary
- Breathlessness (dyspnoea) affects 50–70% of patients with advanced cancer and up to 95% of those with end-stage COPD or heart failure in the palliative phase.
- A thorough assessment using a validated numeric rating scale (NRS 0–10) or the Modified Borg Scale should guide management and be documented at each review.
- Nonpharmacological measures — positioning, hand-held fan therapy, pursed-lip breathing, relaxation techniques, and energy conservation — are first-line interventions for all patients.
- Low-dose opioids (e.g., morphine 2.5–5 mg PO/SC q4h or equivalent) are the most evidence-based pharmacological treatment for chronic breathlessness, even in the absence of pain.
- Opioid-naïve patients should start at 25–50% of the equianalgesic dose used for pain and titrate slowly; respiratory depression at palliative doses is rare.
- Benzodiazepines (e.g., midazolam 2.5 mg SC stat or diazepam 2–5 mg PO nocte) are second-line for refractory breathlessness with significant anxiety or panic, or when opioids alone are insufficient.
- Routine supplemental oxygen does NOT relieve breathlessness in non-hypoxaemic patients; a trial of ambulatory or nasal oxygen is appropriate only when SpO₂ < 90% at rest or on minimal exertion.
- Fan therapy directed at the face is a simple, cost-free intervention with evidence comparable to low-flow oxygen in non-hypoxaemic breathlessness.
- Interdisciplinary palliative care team involvement — including physiotherapy, occupational therapy, psychology, and social work — improves symptom burden and quality of life.
- Anticipatory guidance and advance care planning conversations should be integrated early to reduce patient and carer distress.
- Aboriginal and Torres Strait Islander patients may experience breathlessness within a broader holistic health framework; culturally safe communication and access to community-controlled health services are essential.
- Always consider and address reversible contributors (pleural effusion, bronchospasm, infection, anaemia, anxiety) before escalating symptom-directed therapy.
Introduction & Australian Epidemiology
Breathlessness — the subjective experience of difficult, laboured, or uncomfortable breathing — is one of the most prevalent and distressing symptoms encountered in palliative care. It is a multidimensional phenomenon shaped by physiological impairment, psychological distress, social circumstances, and existential concerns. In the Australian palliative care setting, breathlessness demands a structured, evidence-based approach that integrates nonpharmacological strategies with judicious pharmacotherapy.
The Australian Institute of Health and Welfare (AIHW) reports that chronic respiratory diseases are the fifth leading cause of disease burden, while heart failure affects an estimated 480,000 Australians. In advanced malignancy, 50–70% of patients report moderate-to-severe breathlessness in the last months of life, rising further in the final weeks. For patients with end-stage COPD or interstitial lung disease, this figure approaches 95%. Despite its prevalence, breathlessness remains undertreated: a 2019 Australian palliative care audit found that fewer than 40% of patients with refractory dyspnoea received guideline-concordant opioid therapy.
This article addresses the comprehensive management of breathlessness in the palliative care population, encompassing nonpharmacological measures, opioid therapy, benzodiazepine use, and the role of supplemental oxygen. It is written for Australian primary care physicians, palliative care specialists, and allied health professionals involved in end-of-life symptom management.
Key clinical principle: Breathlessness is a subjective symptom. The patient's self-report of severity is paramount and must guide treatment, not the clinician's objective assessment or oxygen saturation alone.
Nonpharmacological Measures
Nonpharmacological interventions should be offered to every patient with breathlessness as first-line or adjunctive therapy. They are safe, low-cost, and supported by a growing evidence base. Australian palliative care guidelines recommend a multimodal approach combining physical, psychological, and environmental strategies.
Positioning and Postural Optimisation
- Upright or semi-recumbent positioning (elevating the head of bed to 45–90°) reduces diaphragmatic splinting and improves tidal volume.
- Forward lean position (seated, leaning forward onto a table or pillows) engages accessory respiratory muscles and can reduce work of breathing by 10–15%.
- Patients who cannot sit upright may benefit from a side-lying position with the head elevated using wedge pillows or an adjustable hospital bed.
Fan Therapy
- A hand-held fan directed at the face provides a cool air current that stimulates the trigeminal nerve (V2 branch), which reduces the perception of breathlessness via central modulation.
- Randomised controlled trials (Bausewein et al., 2010; Galbraith et al., 2010) demonstrated that fan therapy is non-inferior to nasal oxygen in non-hypoxaemic patients.
- Fan therapy should be demonstrated to the patient and carers and a fan made available at bedside (cost: approximately AUD –10).
Breathing Techniques and Relaxation
- Pursed-lip breathing: Inhalation through the nose for 2 seconds, exhalation through pursed lips for 4 seconds. Reduces respiratory rate, increases tidal volume, and decreases dynamic hyperinflation in COPD.
- Diaphragmatic (abdominal) breathing: The patient places one hand on the chest and one on the abdomen, focusing effort on the abdominal hand to promote diaphragmatic excursion.
- Guided imagery and progressive muscle relaxation may reduce the affective component of breathlessness, particularly when anxiety is prominent.
Energy Conservation and Activity Pacing
- Occupational therapy referral for assessment of activities of daily living (ADLs), prescription of assistive devices (shower chairs, dressing aids), and energy conservation education.
- Prioritisation of activities into essential vs. non-essential, with rest periods planned between exertional tasks.
- Physiotherapy-guided pulmonary rehabilitation or adapted exercise programs where prognosis and functional capacity permit.
Environmental and Psychosocial Measures
- Maintain a cool, well-ventilated room (fan, open window, air conditioning). Temperature control is particularly important in Australian summers.
- Anxiety management: Reassurance, psychoeducation, and cognitive-behavioural strategies. Breathlessness and anxiety form a self-amplifying cycle; addressing the psychological dimension is essential.
- Palliative care liaison and social work input for anticipatory guidance regarding prognosis, advance care planning, and carer support.
Practice point: Fan therapy should be the first intervention trialled alongside positioning. It is free of adverse effects, immediately available, and can be taught to carers in under two minutes.
Opioids
Opioids are the pharmacological mainstay for chronic breathlessness in palliative care. The Cochrane review by Barnes et al. (2016), updated in 2022, confirmed that systemic opioids significantly reduce breathlessness intensity in COPD, heart failure, cancer, and interstitial lung disease. The mechanism involves modulation of central chemoreceptor sensitivity and reduction of the brain's perception of respiratory effort rather than changes in gas exchange.
Dosing Principles
- Start low, titrate slowly. Opioid-naïve patients should begin at approximately 25–50% of the equianalgesic dose used for pain.
- Oral morphine is the first-line agent. If the patient cannot swallow, subcutaneous morphine or subcutaneous fentanyl via a syringe driver are preferred alternatives.
- There is no maximum dose for opioids in breathlessness — titrate to symptom relief balanced against adverse effects.
- Review dose every 24–48 hours during titration. Once stable, review weekly.
Morphine (immediate-release)
MS Mono®, Sevredol® · Opioid analgesic
Adult dose (opioid-naïve)
2.5–5 mg PO q4h PRN; titrate by 2.5–5 mg every 24–48 h
Subcutaneous alternative
1.25–2.5 mg SC q4h or equivalent via syringe driver (24-h dose divided)
Onset / Duration
PO: 30 min onset, 4 h duration · SC: 10–15 min onset, 4 h duration
Renal adjustment
eGFR <30: reduce dose by 50%, extend interval; avoid morphine if eGFR <15 (active metabolite M6G accumulation) — use fentanyl or hydromorphone
Hepatic adjustment
Reduce dose by 50% in severe hepatic impairment (Child-Pugh C)
PBS status
✔ PBS General Benefit
Oxycodone (immediate-release)
Endone® · Opioid analgesic
Adult dose (opioid-naïve)
2.5 mg PO q4h PRN; titrate by 2.5 mg every 24–48 h
Note
Approximately 1.5× potency of oral morphine; useful if morphine not tolerated
Renal adjustment
eGFR <30: reduce dose by 50%, extend interval
PBS status
✔ PBS General Benefit
Fentanyl (subcutaneous)
Sublimaze® · Synthetic opioid
Adult dose (opioid-naïve)
12.5–25 mcg SC q1h PRN or 25–50 mcg/24 h via syringe driver
Advantage in renal impairment
No active metabolites; preferred when eGFR <15 or on dialysis
Onset
SC: 5–10 min · Duration: 1–2 h (bolus); CIVI for sustained effect
PBS status
⚠ PBS Authority Required
Managing Opioid Adverse Effects
- Constipation: Co-prescribe a stimulant laxative (e.g., senna 2 tablets nocte + docusate sodium) from opioid initiation — this is mandatory and does not develop tolerance.
- Nausea: Common in the first 3–5 days. Use haloperidol 0.5–1 mg PO/SC BD or metoclopramide 10 mg PO/SC TDS.
- Drowsiness: Usually transient (3–5 days). If persistent, consider dose reduction or opioid rotation.
- Respiratory depression: At the low doses used for breathlessness, clinically significant respiratory depression is rare. Monitor respiratory rate and sedation score (e.g., Pasero Opioid Sedation Scale) during titration.
Safety alert: Do NOT withhold opioids from breathless patients due to unfounded fear of respiratory depression. Evidence demonstrates that opioids titrated carefully for dyspnoea do not hasten death. Document the clinical rationale and obtain informed consent.
Opioid Rotation
If breathlessness is inadequately controlled or adverse effects are intolerable at effective doses, consider opioid rotation using published equianalgesic tables (e.g., switch morphine to oxycodone, hydromorphone, or fentanyl). Reduce the calculated equianalgesic dose by 25–50% when rotating to account for incomplete cross-tolerance.
Benzodiazepines
Benzodiazepines are second-line agents for breathlessness in palliative care, reserved for situations where anxiety or panic significantly contributes to the symptom experience, or when opioids alone are insufficient. Current evidence (Simon et al., Cochrane 2016; Hui et al., 2023) does not support routine benzodiazepine monotherapy for breathlessness, but they have a defined adjunctive role.
Indications
- Refractory breathlessness with significant anxiety or panic despite optimised opioid therapy and nonpharmacological measures.
- Acute episodes of severe dyspnoea with associated claustrophobia, fear of death, or panic attack.
- End-of-life dyspnoea where sedation is an acceptable or desired effect (e.g., last hours of life, death rattle management).
- Anticipatory anxiety related to breathlessness (e.g., pre-procedural anxiety before thoracentesis).
Midazolam
Hypnovel® · Benzodiazepine
Acute rescue dose
2.5 mg SC/IM stat; repeat after 30 min if needed (max 10 mg in 1 h)
Continuous infusion
5–10 mg/24 h SC via syringe driver as adjunct to opioid
Onset
SC/IM: 2–5 min · IV: 1–3 min
Duration
1–2 h (bolus); CIVI for sustained effect
Renal adjustment
Reduce dose by 50% in severe renal impairment
PBS status
⚠ PBS Authority Required
Diazepam
Ducene®, Valium® · Benzodiazepine
Adult dose
2–5 mg PO nocte or BD; titrate to effect (max 20 mg/day)
Indication
Nocturnal breathlessness with anxiety; anticipatory anxiety
Onset
PO: 15–30 min · Duration: 4–6 h
Caution
Long half-life (20–100 h); accumulation in elderly and hepatic impairment. Prefer lorazepam or oxazepam in frail elderly.
PBS status
✔ PBS General Benefit
Lorazepam
Ativan® · Benzodiazepine
Adult dose
0.5–1 mg PO/SL BD–TDS; titrate cautiously
Advantage
No active metabolites; predictable pharmacokinetics in elderly and renal/hepatic impairment
Onset
SL: 10–15 min · PO: 20–30 min · Duration: 4–6 h
PBS status
⚠ PBS Authority Required
Dosing Principles and Monitoring
- Always optimise opioid therapy first before adding a benzodiazepine.
- Start at the lowest effective dose and titrate in small increments.
- Monitor for excessive sedation (Richmond Agitation-Sedation Scale [RASS] target 0 to −1), respiratory depression, paradoxical agitation, and falls risk.
- In the last hours of life, midazolam 2.5–5 mg SC via syringe driver with morphine is a standard regimen for terminal dyspnoea.
Clinical caution: Benzodiazepines alone are ineffective for breathlessness without an anxiety component. Routine use as monotherapy is not recommended by current evidence. Reserve for adjunctive use when opioids and nonpharmacological measures are optimised.
Oxygen Therapy
The role of supplemental oxygen in palliative breathlessness is one of the most commonly misunderstood areas in clinical practice. A substantial evidence base demonstrates that oxygen does not relieve breathlessness in patients who are not hypoxaemic. The landmark trials by Abernethy et al. (2010) and Bausewein et al. (2010) showed that in non-hypoxaemic patients, nasal oxygen was no more effective than room air delivered by nasal cannulae, while fan therapy was equally effective.
When to Consider Oxygen
Not indicated
SpO₂ ≥ 92% at rest
Oxygen unlikely to provide benefit above placebo effect. Use fan therapy, positioning, and opioids instead.
Community / Palliative care unit
Consider trial
SpO₂ 88–91% at rest or <90% on exertion
Trial of low-flow nasal oxygen (1–2 L/min) for 15–20 min. Continue only if the patient reports subjective improvement. Document response.
Community / Palliative care unit
Indicated
SpO₂ < 88% at rest
Supplemental oxygen is appropriate. Titrate to SpO₂ 88–92%. Consider ambulatory or long-term oxygen therapy (LTOT) if consistent with goals of care.
Any setting
Practical Oxygen Delivery
| Delivery method | Flow rate | FiO₂ (approx.) | Indication |
|---|---|---|---|
| Nasal cannulae | 1–4 L/min | 24–36% | First-line for chronic supplemental O₂; comfortable, allows eating/talking |
| Hudson mask | 4–10 L/min | 35–60% | Higher flow requirements; less comfortable |
| Non-rebreather mask | 10–15 L/min | 60–90% | Acute severe hypoxaemia; end-of-life if distressing |
| Ambulatory portable concentrator | 1–4 L/min | 24–36% | Mobility support for patients on LTOT |
End-of-Life Considerations
- In the last days of life, oxygen therapy may cause physical discomfort (nasal dryness, mask-related claustrophobia) without meaningful symptom relief if the patient is not hypoxaemic.
- Withdrawing oxygen at end of life is ethically appropriate and should be discussed with the patient (where possible) and family. It is not "euthanasia by omission" — the underlying disease is the cause of death.
- If oxygen is withdrawn, increase opioid and/or benzodiazepine doses to manage any worsening dyspnoea and ensure comfort.
- Fan therapy and nonpharmacological measures should be continued or intensified when supplemental oxygen is reduced.
Key message: Do not prescribe home oxygen solely to provide "reassurance" in non-hypoxaemic patients. The false belief that oxygen always relieves breathlessness leads to unnecessary equipment, costs, and can delay appropriate pharmacological management. An honest, compassionate conversation is preferable.
Access and Funding in Australia
- Home oxygen: Funded through state/territory Home Oxygen Programs (HOP) or equivalent. Requires a medical prescription and demonstration of qualifying SpO₂ criteria (typically resting SpO₂ ≤ 88% or ≤ 90% with clinical evidence of cor pulmonale, polycythaemia, or pulmonary hypertension).
- Portable oxygen concentrators may be privately purchased or hired; some state programs provide ambulatory units.
- The National Disability Insurance Scheme (NDIS) may fund oxygen for eligible patients with chronic respiratory disability.
- Equipment suppliers: BOC Healthcare, Air Liquide, Coregas, and various regional providers. Discuss with the patient's palliative care team or respiratory physician.
Pathophysiology of Breathlessness
Understanding the mechanisms of breathlessness in palliative care informs rational therapy. The sensation arises from a mismatch between the brain's expectation of respiratory effort and the afferent signals it receives from central chemoreceptors, peripheral chemoreceptors, pulmonary stretch receptors, and chest wall mechanoreceptors.
Key Mechanisms
- Hypoxic drive: Peripheral chemoreceptors in the carotid and aortic bodies detect arterial PaO₂ < 60 mmHg and transmit signals via the glossopharyngeal and vagus nerves to the brainstem respiratory centres.
- Hypercapnic drive: Central chemoreceptors in the medulla respond to CSF pH changes caused by elevated PaCO₂, increasing ventilatory effort.
- Increased work of breathing: Airway obstruction (COPD, asthma), lung parenchymal restriction (fibrosis, malignancy), chest wall restriction (pleural effusion, kyphoscoliosis), or diaphragmatic dysfunction all increase the effort-to-ventilation ratio.
- Afferent-efferent mismatch: The perception of breathlessness intensifies when the brain detects that respiratory effort is disproportionate to the resulting ventilation — a concept central to the neurophysiological model of dyspnoea.
- Central perception and affect: Anxiety, depression, and previous breathlessness experiences modulate the cortical processing of respiratory signals, amplifying or attenuating the subjective experience.
Opioids are thought to reduce breathlessness by dampening central chemosensitivity and the brain's perception of respiratory effort, without significantly altering respiratory rate or gas exchange at low palliative doses. This mechanism explains why opioids are effective even in patients with normal blood gases.
Clinical Assessment & Diagnostic Approach
A structured assessment of breathlessness in the palliative patient should identify the severity, likely causes, treatable precipitants, and the impact on function and quality of life. Not all breathlessness requires (or is amenable to) aggressive investigation; the intensity of assessment should be guided by the patient's goals of care.
Assessment Tools
Essential
Numeric Rating Scale (NRS 0–10)
Patient self-report of breathlessness intensity; use at every encounter to guide titration.
Available
Modified Borg Scale
0–10 categorical scale; useful during exertion or exercise testing.
Available
Cancer Dyspnoea Scale (CDS)
Validated 12-item scale covering sense of effort, anxiety, and discomfort. Useful in oncology populations.
Available
Palliative Care Outcome Scale (POS)
Includes breathlessness item as part of multidimensional symptom assessment.
Investigations — When Appropriate to Goals of Care
Essential
Pulse oximetry (SpO₂)
Bedside; guides oxygen therapy decisions. Available in all settings.
Available
Chest X-ray
Assess for pleural effusion, pneumonia, pneumothorax, disease progression. MBS item 58500.
Available
Full blood count (FBC)
Detect anaemia (Hb <80 g/L may contribute to dyspnoea); guide transfusion decisions.
Available
BNP / NT-proBNP
If decompensated heart failure suspected; BNP >400 pg/mL supports diagnosis.
Specialist
Arterial blood gas (ABG)
Invasive; reserved for uncertain oxygenation status or hypercapnia concerns. Requires arterial access.
Specialist
CT pulmonary angiogram (CTPA)
If pulmonary embolism suspected and investigation aligns with goals of care. MBS item 57358.
Reversible Causes to Consider
| Cause | Clues | Intervention |
|---|---|---|
| Pleural effusion | Unilateral dullness, reduced breath sounds, mediastinal shift on CXR | Thoracentesis or intercostal drain; talc pleurodesis if recurrent |
| Bronchospasm | Wheeze, prolonged expiratory phase, history of COPD/asthma | Salbutamol nebuliser 5 mg PRN ± ipratropium 500 mcg; consider prednisolone 25–50 mg for 5 days |
| Infection | Fever, productive cough, raised WCC/CRP | Antibiotics if consistent with goals of care; amoxicillin 500 mg TDS or doxycycline 200 mg stat then 100 mg daily |
| Anaemia | Hb <80 g/L, pallor, fatigue | Red cell transfusion if symptomatic and consistent with goals of care |
| Anxiety / Panic | Tremor, hyperventilation, catastrophic cognitions | Nonpharmacological strategies ± benzodiazepine as above |
| Superior vena cava obstruction | Facial/upper limb swelling, prominent chest wall veins | Dexamethasone 8 mg IV + urgent oncology/radiology referral for stenting or radiotherapy |
Special Populations
Pregnancy
Nonpharmacological measures first
Positioning (left lateral, elevated head of bed), fan therapy, breathing techniques. All safe in pregnancy.
Opioids
Use with caution; morphine crosses the placenta. Short-term use for refractory symptoms is acceptable in palliative context. Monitor neonate for respiratory depression if delivery is imminent. Fentanyl may have a slightly more favourable profile.
Benzodiazepines
Category D (AU). Risk of neonatal flaccidity, respiratory depression, and withdrawal. Use only when benefits clearly outweigh risks (e.g., terminal dyspnoea in maternal oncology).
Oxygen
Safe; same SpO₂ thresholds apply. Target SpO₂ 92–96% to ensure adequate fetal oxygenation.
Paediatrics
Assessment
Age-appropriate tools: Children's Dyspnoea Scale (for ≥7 years), faces scale, or parent/observer report using the Pediatric Palliative Care Symptom Assessment.
Nonpharmacological
Positioning, fan therapy (with parental education), distraction techniques, music therapy. Engage child life therapists where available.
Opioids
Morphine 0.1–0.2 mg/kg PO q4h (opioid-naïve) or 0.05–0.1 mg/kg SC q4h. Titrate in 25% increments. Subcutaneous fentanyl 0.5–1 mcg/kg q1h PRN or via syringe driver.
Benzodiazepines
Midazolam 0.05–0.1 mg/kg SC/IV stat (max 2.5 mg per dose) or 0.2–0.5 mg/kg/24 h via syringe driver. Oral lorazepam 0.02–0.05 mg/kg BD–TDS for anxiety-related dyspnoea.
Oxygen
Paediatric nasal cannulae at 0.5–2 L/min. Same principles: only if hypoxaemic (SpO₂ <90%).
Elderly (≥75 years)
Opioids
Start at 50% of standard starting dose. Morphine clearance decreases with age; prolonged half-life. Monitor for excessive sedation, falls, constipation. Consider renal function.
Benzodiazepines
Use lorazepam or oxazepam (no active metabolites, predictable pharmacokinetics) rather than diazepam. Reduce dose by 50%. Risk of delirium, falls, and paradoxical agitation is increased.
Oxygen
Same thresholds; ensure adequate humidification and skin protection at cannulae site.
Renal Impairment
Morphine
AVOID if eGFR <15 mL/min or on dialysis. Active metabolites (M3G, M6G) accumulate → neurotoxicity, respiratory depression. Use fentanyl or hydromorphone instead.
Fentanyl
Preferred opioid in severe renal impairment. No active metabolites. Dose reduction generally not required unless on dialysis (dose after dialysis).
Benzodiazepines
Midazolam: reduce dose by 50% in severe renal impairment. Lorazepam: use with caution; glucuronide metabolites are renally cleared.
Hepatic Impairment
Opioids
Reduce all opioid doses by 50% in Child-Pugh C cirrhosis. Morphine, oxycodone, and hydromorphone all undergo hepatic metabolism. Monitor closely for sedation and respiratory depression. Fentanyl requires dose reduction in severe impairment.
Benzodiazepines
Avoid long-acting agents (diazepam, clonazepam). Lorazepam (glucuronidation, less affected) or oxazepam are preferred but still require dose reduction.
Immunocompromised
Infection assessment
In immunocompromised patients with new or worsening breathlessness, maintain a low threshold for infection screening (sputum culture, blood cultures, chest CT) as infective aetiologies may present atypically (e.g., no fever, normal WCC).
Drug interactions
Check for interactions between opioids/benzodiazepines and immunosuppressant medications (e.g., azole antifungals inhibit CYP3A4, increasing benzodiazepine levels).
Pneumocystis / fungal pneumonia
Consider PJP (trimethoprim-sulfamethoxazole) or invasive fungal infection if subacute breathlessness with ground-glass changes on imaging — if investigation aligns with goals of care.
Monitoring
Effective management of breathlessness requires ongoing monitoring with documentation at defined intervals. The monitoring plan should be tailored to the care setting (community, inpatient palliative care, hospice, hospital) and the patient's goals of care.
Monitoring Parameters
| Parameter | Frequency | Tool / Method | Action threshold |
|---|---|---|---|
| Breathlessness intensity | Every review (at least daily inpatient; weekly community) | NRS 0–10 or Modified Borg | NRS increase ≥2 from baseline → reassess cause and escalate therapy |
| SpO₂ | At each assessment if oxygen in use or being considered | Pulse oximetry | SpO₂ <88% → initiate/escalate O₂; SpO₂ ≥92% with O₂ → trial cessation |
| Respiratory rate | With each opioid dose change; daily if on continuous infusion | Count over 30 sec × 2 | RR <8/min or excessive sedation (RASS ≤ −3) → withhold opioid, consider naloxone |
| Sedation level | Every opioid/benzodiazepine dose adjustment | Pasero Opioid Sedation Scale or RASS | Score ≥3 (somnolent, difficult to rouse) → withhold dose, review |
| Functional status | Weekly or at clinical change | Australia-modified Karnofsky Performance Status (AKPS) or Palliative Performance Scale (PPS) | Decline in AKPS ≥10 points → reassess treatment plan and goals |
| Adverse effects | Daily during titration; weekly when stable | Clinical assessment (bowel function, nausea, sedation) | Constipation → ensure laxatives are prescribed; nausea → add anti-emetic |
Stepwise Escalation
1
Nonpharmacological measures alone
Positioning, fan therapy, breathing techniques, environmental modification, psychosocial support.
2
Add low-dose opioid
Morphine 2.5–5 mg PO q4h PRN or equivalent; titrate for effect.
3
Optimise opioid + consider oxygen trial
Increase opioid dose; trial nasal O₂ if SpO₂ <90%. Continue if subjective benefit.
4
Add benzodiazepine
Midazolam 2.5 mg SC or lorazepam 0.5 mg PO if refractory dyspnoea with anxiety persists.
5
Continuous infusion at end of life
Syringe driver: morphine + midazolam SC CIVI for ongoing comfort in the last days.
Aboriginal and Torres Strait Islander Health Considerations
Aboriginal and Torres Strait Islander Health
Aboriginal and Torres Strait Islander Australians experience significantly higher rates of chronic respiratory disease, cardiovascular disease, and advanced-stage cancer diagnosis than non-Indigenous Australians. The AIHW reports that Indigenous Australians are 2.5 times more likely to die from chronic respiratory disease and have a life expectancy gap of approximately 8 years. These disparities profoundly affect the burden of breathlessness in palliative care.
Cultural safety is paramount. The concept of health for Aboriginal and Torres Strait Islander peoples is holistic — encompassing physical, social, emotional, cultural, and spiritual wellbeing (as defined by the National Aboriginal Community Controlled Health Organisation [NACCHO]). Breathlessness may be understood within this broader framework, and management plans should respect cultural perspectives on illness, death, and dying.
Key resource: The Palliative Care Australia — National Palliative Care Standards and Guidelines for Aboriginal and Torres Strait Islander Palliative Care (PCATSI Partnership) provide detailed frameworks for culturally safe palliative care delivery. Refer also to RHDAustralia for chronic disease management in Indigenous communities.
📚 References
- 1. Barnes H, McDonald J, Smallwood N, Manser R. Opioids for the palliation of refractory breathlessness in adults with advanced disease and terminal illness. Cochrane Database Syst Rev. 2016;3(3):CD011008. Updated 2022.
- 2. Abernethy AP, McDonald CF, Frith PA, et al. Effect of palliative oxygen versus room air in relief of breathlessness in patients with refractory dyspnoea: a double-blind, randomised controlled trial. Lancet. 2010;376(9743):784–793.
- 3. Bausewein C, Booth S, Gysels M, Higginson I. Non-pharmacological interventions for breathlessness in advanced stages of malignant and non-malignant diseases. Cochrane Database Syst Rev. 2008;(2):CD005623.
- 4. Galbraith S, Fagan P, Perkins P, Lynch A, Booth S. Does the use of a handheld fan improve chronic dyspnea? A randomized, controlled, crossover trial. J Pain Symptom Manage. 2010;39(5):831–838.
- 5. Simon ST, Higginson IJ, Booth S, Harding R, Bausewein C. Benzodiazepines for the relief of breathlessness in advanced malignant and non-malignant diseases in adults. Cochrane Database Syst Rev. 2016;10(10):CD007354.
- 6. Hui D, Bohlke K, Bao T, et al. Management of dyspnea in advanced cancer: ASCO guideline update. J Clin Oncol. 2023;41(12):2227–2249.
- 7. Palliative Care Australia. National Palliative Care Standards. 5th ed. Canberra: Palliative Care Australia; 2018.
- 8. Australian Institute of Health and Welfare (AIHW). Aboriginal and Torres Strait Islander Health Performance Framework. Canberra: AIHW; 2023.
- 9. Parshall MB, Schwartzstein RM, Adams L, et al. An official ATS statement: update on the mechanisms, assessment, and management of dyspnea. Am J Respir Crit Care Med. 2012;185(4):435–452.
- 10. Currow DC, McDonald C, Oaten S, et al. Once-daily opioids for chronic dyspnea: a dose increment and pharmacovigilance study. J Pain Symptom Manage. 2011;42(3):388–399.
- 11. National Aboriginal Community Controlled Health Organisation (NACCHO). Core Functions and Practice Standards for Aboriginal Community Controlled Health Services. Canberra: NACCHO; 2020.
- 12. Johnson MJ, Bland JM, Oxberry SG, et al. Opioids for breathlessness: a systematic review and meta-analysis. BMJ Support Palliat Care. 2013;3(2):153–162.
- 13. Ekström M, Bajwah S, Bland JM, Currow DC, Hussain J, Johnson MJ. One evidence base; three stories: do opioids relieve chronic breathlessness? Thorax. 2018;73(1):88–90.
- 14. Farquhar MC, Prevost AT, McCrone P, et al. The Clinical and Cost Effectiveness of a Breathlessness Intervention Service for Patients with Palliative Care Needs: A Randomised Controlled Trial. PLoS Med. 2014;11(6):e1001640.
- 15. Wiseman R, Rowett D, Allcroft P, Abernethy A, Currow D. Chronic refractory breathlessness — a clinical conundrum. Aust Fam Physician. 2013;42(12):862–866.